The DESTINY-Breast09 study, reported at ASCO, compared antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) and Roche's HER2 antibody, Perjeta (pertuzumab), to the widely used THP ...

Enhertu is already approved as a second-line or later therapy for HER2-positive breast cancer based on the results of the DESTINY-Breast03 trial, as well as several other indications, including HR ...

Event-free survival after the confirmatory adjuvant trial completed recruitment was numerically better with pertuzumab plus trastuzumab than with ... EGFR siRNA was delivered into HER2-expressing ...